Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis (Q37496549)

20 August 2017

0 references

1 reference

title

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis (English)

1 reference

20 August 2017

0 references

1 reference

irritable bowel syndrome

1 reference

1

Alexander C Ford

0 references

Paul Moayyedi

object named as

Paul Moayyedi

6

0 references

author name string

Lawrence J Brandt

2

1 reference

20 August 2017

Christine Young

3

1 reference

20 August 2017

William D Chey

4

1 reference

20 August 2017

Amy E Foxx-Orenstein

5

1 reference

20 August 2017

language of work or name

English

0 references

publication date

26 May 2009

1 reference

The American Journal of Gastroenterology

20 August 2017

1 reference

20 August 2017

104

1 reference

20 August 2017

1831-43; quiz 1844

1 reference

20 August 2017

7

1 reference

Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population.

20 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1. Definition of IBS and colonic motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Meta-analysis: The treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

An evidence-based position statement on the management of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Effect of renzapride on transit in constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Nonsteroidal anti-inflammatory drugs for low back pain: an updated Cochrane review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.223

21 January 2018

Identifiers

DOI

10.1038/AJG.2009.223

1 reference

release_pwvkk4ppofbhxoxbzbkmpzhrda

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pwvkk4ppofbhxoxbzbkmpzhrda

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference